Weyerhaeuser Free cash flow decreased by 85.7% to $29.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 39.6%, from $48.00M to $29.00M. Over 3 years (FY 2021 to FY 2024), Free cash flow shows a downward trend with a -32.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.30B | $652.00M | $478.00M | $937.00M | $1.14B | $554.00M | $152.00M | $105.00M | $484.00M | $514.00M | $273.00M | $102.00M | $423.00M | $226.00M | $205.00M | $48.00M | $388.00M | $203.00M | $29.00M |
| QoQ Change | — | -49.8% | -26.7% | +96.0% | +21.2% | -51.2% | -72.6% | -30.9% | +361.0% | +6.2% | -46.9% | -62.6% | +314.7% | -46.6% | -9.3% | -76.6% | +708.3% | -47.7% | -85.7% |
| YoY Change | — | — | — | — | -12.5% | -15.0% | -68.2% | -88.8% | -57.4% | -7.2% | +79.6% | -2.9% | -12.6% | -56.0% | -24.9% | -52.9% | -8.3% | -10.2% | -39.6% |